An Exploratory Open Label, Three-way Crossover Study to Compare the Pharmacokinetic Profiles of Three Different YM178 Modified Release (OCAS) Formulations Under Fasted and Fed Conditions With YM178 Immediate Release (IR) Formulation Under Fasted Conditions in Healthy Subjects
Latest Information Update: 14 Jan 2020
At a glance
- Drugs Mirabegron (Primary)
- Indications Overactive bladder; Urination disorders
- Focus Pharmacokinetics
- Sponsors Astellas Pharma
- 01 Jul 2013 Actual patient number changed from 36 to 34 according to ClinicalTrials.gov.
- 27 Jul 2012 New trial record